Fosalvudine

Structural formula
	Mixture of two diastereomers
General
Non-proprietary name	Fosalvudine tidoxil
other names	Fosalvudinum tidoxilum ( Latin ); (2 RS ) -2- (decyloxy) -3 - [(dodecyl) sulfanyl] propyl {(2 R , 3 S , 5 R ) -3-fluoro-5- [5-methyl-2,4-dioxo-3 , 4-dihydropyrimidin-1 (2 H ) -yl] tetrahydrofuran-2-yl} methyl hydrogen phosphate ( IUPAC );
Molecular formula	C 35 H 64 FN 2 O 8 PS
External identifiers / databases
PubChem	11563925
ChemSpider	9738697
Wikidata	Q1439344
Drug information
Drug class	Antiviral agent , nucleoside reverse transcriptase inhibitors
Mechanism of action	Competitive inhibition of reverse transcriptase
properties
Molar mass	722.93 g mol −1
safety instructions
GHS hazard labeling ; no classification available
GHS hazard labeling ; no classification available
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Fosalvudin or Fosalvudin tidoxil (manufacturer: Heidelberg Pharma ; trade name: Tidoxil ) is an experimental drug for the treatment of HIV- infected patients as part of a HAART .

It belongs to the group of nucleoside reverse transcriptase inhibitors (NRTIs).

history

Fosalvudine is currently being developed by Heidelberg Pharma.

chemistry

The drug is a mixture of diastereomers .

Pharmacokinetics

Fosalvudine is selectively distributed in various organ systems through the prodrug formulation. In particular in lymphoid tissue, but not in the bone marrow . The concentrations in plasma and CSF were comparable.

Fosalvudine has a significantly longer plasma half-life compared to AZT . This means that it can be taken once a day.

Side effects

No fatal side effects were observed in phase I studies.

Resistances

Nothing has yet been published about resistance.

Individual evidence

↑ International Nonproprietary Names for Pharmaceutical Substances (INN) (PDF; 966 kB), WHO Drug Information, Vol. 21, No. 1, 2007, p. 66.
↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
↑ ^a ^b ^c Heidelberg Pharma: Biotechnology / Life Sciences in Baden-Württemberg Development of new active ingredients against AIDS ( memento from July 25, 2015 in the web archive archive.today ), accessed on July 25, 2015.

[1] International Nonproprietary Names for Pharmaceutical Substances (INN) (PDF; 966 kB), WHO Drug Information, Vol. 21, No. 1, 2007, p. 66.

[NV-2] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[Heidelberg_Pharma-3] Heidelberg Pharma: Biotechnology / Life Sciences in Baden-Württemberg Development of new active ingredients against AIDS ( memento from July 25, 2015 in the web archive archive.today ), accessed on July 25, 2015.